OR WAIT null SECS
January 13, 2016
The collaboration will focus on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
November 17, 2015
BioOutsource releases informational video detailing issues associated with ADCC assays and how to effectively analyze them.
October 27, 2015
Catalent’s SMARTag™ technology enables biologic innovators to develop more efficacious antibody drug conjugates. It allows site-specific, programmable drug placement using proprietary cytotoxin-linkers/conjugation chemistry in an efficient and scalable process.
October 02, 2015
The development of successful ADCs involves careful selection of drug, antibody, and linker, as well as choosing the right attachment chemistry to link the cytotoxic to the antibody.
September 29, 2015
The CDMO is striving to become a market leader in the development and manufacturing of antibody-drug conjugates.
September 25, 2015
There is growing interest in the development of liquid formulations in prefilled syringes and autoinjectors, which offer convenience and ease of administration in a home setting.
January 15, 2015
Catalent Pharma Solutions and Sanofi-Aventis R&D have entered into a collaboration to develop Sanofi’s proprietary antibodies using Catalent’s SMARTag antibody drug conjugate (ADC) platform.
April 01, 2014
Advanced drug delivery technologies can increase efficacy and safety, extend patent lives, and provide competitive differentiation for biopharmaceuticals.
May 02, 2012
The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.